BQNAT is a Bedaquiline-based treatment regimen specifically designed for drug-resistant Tuberculosis (TB) cases following a confirmed negative CBNAAT (Cartridge-Based Nucleic Acid Amplification Test) for rifampicin resistance. Utilized mainly in India under the National TB Elimination Program (NTEP), BQNAT targets rifampicin-resistant TB (RR-TB) and multidrug-resistant TB (MDR-TB), including extensively drug-resistant TB (XDR-TB) patients. The treatment core includes Bedaquiline (BDQ), combined with antibiotics such as Levofloxacin or Moxifloxacin, Linezolid, Clofazimine, and Cycloserine. This regimen is administered for 18 to 20 months with regular patient monitoring of ECG, liver function, electrolytes, and drug adherence to ensure safety and efficacy. BQNAT is established based on India's NTEP guidelines after thorough diagnosis via CBNAAT and Line Probe Assay (LPA). This regimen supports therapeutic success in drug-resistant TB management, reducing resistance spread and enhancing patient outcomes in clinical and public health settings.
Key Features
| Features | Description |
|---|---|
| Core Drug | Bedaquiline (BDQ) – key anti-TB drug for resistant strains |
| Companion Drugs | Levofloxacin or Moxifloxacin, Linezolid, Clofazimine, Cycloserine |
| Treatment Duration | 18-20 months depending on patient response |
| Indications | Rifampicin-resistant TB (RR-TB), MDR-TB, XDR-TB cases |
| Diagnostic Prerequisite | Negative CBNAAT test with detected rifampicin resistance confirmed through Line Probe Assay (LPA) |
| Monitoring Parameters | ECG, liver function tests, electrolytes, adherence checks |
| Program Affiliation | Implemented under India’s National TB Elimination Program (NTEP) |
| Therapeutic Goal | Effective management and cure of drug-resistant TB to reduce transmission |
| Patient Eligibility | Confirmed MDR-TB patients eligible for Bedaquiline regimen |
| Attributes | Description |
|---|---|
| Regimen Type | Bedaquiline-based drug-resistant TB treatment |
| Target Condition | Drug-resistant tuberculosis including RR-TB, MDR-TB, XDR-TB |
| Diagnostic Tests Required | CBNAAT for rifampicin resistance, Line Probe Assay (LPA) for detailed drug susceptibility |
| Treatment Duration | 18-20 months |
| Drugs Included | Bedaquiline, Levofloxacin/Moxifloxacin, Linezolid, Clofazimine, Cycloserine |
| Monitoring Requirements | ECG, liver function tests, electrolytes, drug adherence |
| Regulatory Program | National TB Elimination Program (NTEP), India |
| Administration Method | Oral medication combination regimen |
| Patient Monitoring Frequency | Regular intervals throughout treatment duration |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
Patient eligibility for BQNAT is confirmed through a negative CBNAAT test indicating rifampicin resistance, followed by drug susceptibility confirmation with Line Probe Assay (LPA).
The BQNAT regimen is administered over 18 to 20 months depending on the patient's clinical response and drug tolerability.
The regimen core drugs include Bedaquiline, Levofloxacin or Moxifloxacin, Linezolid, Clofazimine, and Cycloserine.
Regular monitoring includes ECG for cardiac health, liver function tests, electrolyte levels, and close monitoring of medication adherence.
Yes, BQNAT is implemented under the Indian National TB Elimination Program (NTEP) guidelines designed for managing drug-resistant TB.
Yes, BQNAT is suitable for extensively drug-resistant TB cases once rifampicin resistance and further susceptibility patterns are confirmed.
Country Of Origin: India
BQNAT = Bedaquiline-based treatment following a Negative CBNAAT test
CBNAAT = Cartridge-Based Nucleic Acid Amplification Test (like GeneXpert)
BQNAT regimen is used for drug-resistant TB cases when:
Rifampicin resistance is detected
Patient is eligible for Bedaquiline-containing regimen
Confirmed MDR-TB or XDR-TB, often through Line Probe Assay (LPA) and CBNAAT
BQNAT Regimen – Overview (India’s NTEP Guidelines)
Core Drugs (may vary slightly):
Bedaquiline (BDQ)
Levofloxacin (Lfx) or Moxifloxacin (Mfx)
Linezolid (Lzd)
Clofazimine (Cfz)
Cycloserine (Cs)
Duration: 18–20 months, depending on patient response and tolerability
Regular monitoring: ECG, liver function, electrolytes, adherence
Used In:
Patients with rifampicin-resistant TB (RR-TB) or MDR-TB
If CBNAAT detects Rif resistance, and DST (Drug Susceptibility Testing) guides further drug inclusion
Implemented under National TB Elimination Program (NTEP), India
If you're referring to something else by BQNAT (e.g., a lab test, a program, or a specific guideline), feel free to clarify!
Ask ChatGPT
